[go: up one dir, main page]

BR0110234A - Agentes anti-hipertensivos e uso - Google Patents

Agentes anti-hipertensivos e uso

Info

Publication number
BR0110234A
BR0110234A BR0110234-6A BR0110234A BR0110234A BR 0110234 A BR0110234 A BR 0110234A BR 0110234 A BR0110234 A BR 0110234A BR 0110234 A BR0110234 A BR 0110234A
Authority
BR
Brazil
Prior art keywords
antihypertensive agents
alkynyl
alkenyl
alkyl
carboxyalkyl ether
Prior art date
Application number
BR0110234-6A
Other languages
English (en)
Inventor
Bruce Jeffrey Auerbach
Karen Diane Hitchcock
Michael John Ryan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0110234A publication Critical patent/BR0110234A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"AGENTES ANTI-HIPERTENSIVOS E USO". A invenção é uma composição farmacêutica que compreende um carboxialquiléter de fórmula (1) em que R~ 1~, R~ 2~, R~ 3~ e R~ 4~ incluem alquila, alquenila e alquinila, m e n são números inteiros de 2 a 9, Y~ 1~ e Y~ 2~ incluem COOH, CHO, tetrazol, COOR~ 5~ em que R~ 5~ é alquila, alquenila ou alquinila ou um sal farmaceuticamente aceitável da mesma e um agente antihipertensivo, a dita composição sendo útil para o tratamento de doenças cardiovasculares. A invenção inclui um processo para o tratamento da hipertensão que compreende administrar um carboxialquiléter.
BR0110234-6A 2000-04-26 2001-03-22 Agentes anti-hipertensivos e uso BR0110234A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19985500P 2000-04-26 2000-04-26
US24228000P 2000-10-20 2000-10-20
PCT/US2001/009088 WO2001080847A2 (en) 2000-04-26 2001-03-22 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use

Publications (1)

Publication Number Publication Date
BR0110234A true BR0110234A (pt) 2003-03-05

Family

ID=26895229

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110234-6A BR0110234A (pt) 2000-04-26 2001-03-22 Agentes anti-hipertensivos e uso

Country Status (34)

Country Link
EP (1) EP1280522B1 (pt)
JP (1) JP2003531170A (pt)
KR (1) KR20020091245A (pt)
CN (1) CN1426299A (pt)
AP (1) AP2002002665A0 (pt)
AR (1) AR031104A1 (pt)
AT (1) ATE283691T1 (pt)
AU (1) AU2001247658A1 (pt)
BG (1) BG107264A (pt)
BR (1) BR0110234A (pt)
CA (1) CA2405559A1 (pt)
CZ (1) CZ20023459A3 (pt)
DE (1) DE60107559T2 (pt)
DO (1) DOP2001000150A (pt)
EA (1) EA005245B1 (pt)
EE (1) EE200200611A (pt)
ES (1) ES2231470T3 (pt)
HR (1) HRP20020936A2 (pt)
HU (1) HUP0300403A3 (pt)
IL (1) IL152474A0 (pt)
IS (1) IS6570A (pt)
MA (1) MA26894A1 (pt)
MX (1) MXPA02009662A (pt)
NO (1) NO20025135L (pt)
NZ (1) NZ521713A (pt)
OA (1) OA12252A (pt)
PA (1) PA8516001A1 (pt)
PE (1) PE20011308A1 (pt)
PL (1) PL357906A1 (pt)
PT (1) PT1280522E (pt)
SK (1) SK15132002A3 (pt)
SV (1) SV2002000367A (pt)
TN (1) TNSN01061A1 (pt)
WO (1) WO2001080847A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1045691T1 (en) * 1997-12-12 2005-04-30 Warner-Lambert Company Llc Statin-carboxyalkylether combinations
CN102875478A (zh) * 2007-06-21 2013-01-16 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐
DE102008026033B4 (de) * 2008-05-30 2017-08-24 Voith Patent Gmbh Antriebsstrang mit einer hydrodynamischen Maschine
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
SV2002000367A (es) 2002-08-26
DOP2001000150A (es) 2002-08-15
IL152474A0 (en) 2003-05-29
HUP0300403A3 (en) 2005-03-29
TNSN01061A1 (en) 2005-11-10
NO20025135D0 (no) 2002-10-25
MA26894A1 (fr) 2004-12-20
JP2003531170A (ja) 2003-10-21
IS6570A (is) 2002-09-27
DE60107559D1 (de) 2005-01-05
KR20020091245A (ko) 2002-12-05
EA200200953A1 (ru) 2003-04-24
DE60107559T2 (de) 2005-04-14
BG107264A (en) 2003-07-31
CZ20023459A3 (cs) 2003-05-14
PT1280522E (pt) 2005-02-28
NZ521713A (en) 2004-09-24
SK15132002A3 (sk) 2003-08-05
AR031104A1 (es) 2003-09-10
CN1426299A (zh) 2003-06-25
EP1280522B1 (en) 2004-12-01
NO20025135L (no) 2002-11-27
PL357906A1 (en) 2004-08-09
EP1280522A2 (en) 2003-02-05
WO2001080847A2 (en) 2001-11-01
ATE283691T1 (de) 2004-12-15
AU2001247658A1 (en) 2001-11-07
MXPA02009662A (es) 2003-03-10
EA005245B1 (ru) 2004-12-30
HRP20020936A2 (en) 2004-12-31
OA12252A (en) 2006-05-11
PA8516001A1 (es) 2002-09-17
WO2001080847A3 (en) 2002-07-18
PE20011308A1 (es) 2002-01-18
AP2002002665A0 (en) 2002-12-31
EE200200611A (et) 2004-06-15
ES2231470T3 (es) 2005-05-16
HUP0300403A2 (hu) 2003-06-28
CA2405559A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
PA8452201A1 (es) Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4"sustituidos.
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
BR0111127A (pt) Métodos e composições para tratamento do vìrus de hepatite c
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
FR2808685B1 (fr) Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
BR9813208A (pt) Antagonista receptor de vitronectina
PT1251846E (pt) Taxanos com carbonato c-4
NO20032261D0 (no) Medisinske preparater
BR0205812A (pt) Benzimidazois úteis no tratamento da disfunção sexual
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
BR0110234A (pt) Agentes anti-hipertensivos e uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.